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CancerThe critical importance of dystrophin to cardiomyocyte contraction and sarcolemmal andmyoﬁbers integrity, led
us to test the hypothesis that dystrophin reduction/loss could be involved in the pathogenesis of doxorubicin-
induced cardiomyopathy, in order to determine a possible speciﬁc structural culprit behind heart failure. Rats
received total cumulative doses of doxorubicin during 2 weeks: 3.75, 7.5, and 15 mg/kg. Controls rats received
saline. Fourteen days after the last injection, heartswere collected for light and electronmicroscopy, immunoﬂu-
orescence and western blot. The cardiac function was evaluated 7 and 14 days after drug or saline. Additionally,
dantrolene (5 mg/kg), a calcium-blocking agent that binds to cardiac ryanodine receptors, was administered
to controls and doxorubicin-treated rats (15 mg/kg). This study offers novel and mechanistic data to clarify mo-
lecular events that occur in the myocardium in doxorubicin-induced chronic cardiomyopathy. Doxorubicin
led to a marked reduction/loss in dystrophin membrane localization in cardiomyocytes and left ventricular
dysfunction, whichmight constitute, in association with sarcomeric actin/myosin proteins disruption, the struc-
tural basis of doxorubicin-induced cardiac depression. Moreover, increased sarcolemmal permeability suggests
functional impairment of the dystrophin-glycoprotein complex in cardiac myoﬁbers and/or oxidative damage.
Increased expression of calpain, a calcium-dependent protease, was markedly increased in cardiomyocytes
of doxorubicin-treated rats. Dantrolene improved survival rate and preserved myocardial dystrophin,
calpain levels and cardiac function, which supports the opinion that calpain mediates dystrophin loss and myo-
ﬁbrils degradation in doxorubicin-treated rats. Studies are needed to further elucidate this mechanism, mainly
regarding speciﬁc calpain inhibitors, which may provide new interventional pathways to prevent doxorubicin-
induced cardiomyopathy.olecular Cardiology, Department
ersity of São Paulo, 14049-900
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Doxorubicin (Adriamycin®), an anthracycline antibiotic, is one
of the most important anticancer therapeutic drugs. The major factor
limiting its clinical use is its cardiotoxic effect. This manifests as elec-
trophysiological abnormalities after one dose of doxorubicin, clinical-
ly controllable, or chronic cardiotoxicity, dependent on cumulative
doses of doxorubicin, a more common and clinically most relevant
form of myocardial damage, which results in cardiomyopathy and
heart failure (Sun et al., 2001; Takemura and Fujiwara, 2007). There-
fore, an efﬁcient strategy to reduce or prevent cardiac complicationsis needed so higher doses could be employed with increasing cancer
cure rates. It is accepted that the intrinsic mechanism of the cardio-
toxic effect is distinct from that responsible for its antineoplasic
effect attributed to DNA intercalation and topoisomerase II inhibition
(Keizer et al., 1990).
The main hypothesis of doxorubicin cardiotoxicity implicates oxi-
dative stress (Doroshow, 1983; Takemura and Fujiwara, 2007). It is
assumed that radical reactions are catalyzed by iron that abrogates
the antioxidant defenses of cardiomyocytes. Dexrazoxane, the only
cardioprotective currently available, is an intracellular chelator that
acts by removing iron from its complex with doxorubicin (Armstrong,
2004; Spallarossa et al., 2004). However, the oxidative stress mecha-
nism has been increasingly questioned. Other mechanisms include
decreased levels of antioxidants and sulfhydryl groups, inhibition
of nucleic acids and protein synthesis, release of vasoactive amines,
altered adrenergic function, and downregulation of genes (Gianni
et al., 2008; Takemura and Fujiwara, 2007).
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toxicity have been reported, few pay particular attention to the
nature of structural modiﬁcations at the intracellular level that
may open new interventional routes to prevent doxorubicin cardio-
toxicity. In some ways, the cytoskeletal apparatus has been linked
to doxorubicin cardiotoxic effect, such as impairment of the actin–
myosin interaction (Bottone et al., 1998), desmin disruption and for-
mation of cytoplasmic aggregates of desmin (Fischer et al., 2005; Liu
et al., 2006; Sterba et al., 2011), and sarcomeric myosin disorganiza-
tion (Sardão et al., 2009).
The critical importance of dystrophin, a key component of the
dystrophin–glycoprotein complex that connects the cytoskeleton
and the extracellular matrix, to cardiomyocyte contraction and sarco-
lemmal and myoﬁber integrity (Danialou et al., 2001; Lapidos et al.,
2004; Tidball and Wehling-Henricks, 2007), which has also been sug-
gested as a common route to the induction of cardiomyopathy and
heart failure (Celes et al., 2010; Kawada et al., 2005; Toyo-Oka et
al., 2004), led us to hypothesize that the loss of dystrophin could be in-
volved in doxorubicin-induced cardiomyopathy in wild rats with nor-
mal expression of myocardium dystrophin, in order to determine a
possible speciﬁc structural culprit associatedwith cardiac dysfunction.
2. Materials and methods
2.1. Animals
Male Wistar rats (200–215 g), from the breeding colony of the
Faculty of Medicine of Ribeirão Preto, were used. Theyweremaintained
in a temperature (22–24 °C) and light–dark (12:12 h) controlled room
receiving standard rat chow and water ad libitum. All the experimental
procedureswere approved by theAnimal Care Committee of the Faculty
of Medicine of Ribeirão Preto (Process 138/2009).
2.2. Experimental protocol
The animals were allocated into four groups: three doxorubicin-
treated groups using three different doses and a control group. The
doxorubicin hydrochloride (Rubidox, Bergamo Ltda., Taboão da
Serra, São Paulo, Brazil) was administered intraperitoneally to rats
in six equal injections over a period of two weeks, in total cumulative
doses of 3.75 mg/kg, 7.5 mg/kg and 15 mg/kg of body weight, a
chronic model of doxorubicin-induced congestive heart failure in
rats previously proposed (Siveski-Iliskovic et al., 1994). Doxorubicin
solutionwas preparedwith physiological saline under sterile conditions
immediately before injection. Control group received six intraperitoneal
injections of physiological saline in the same regimen and volume as
doxorubicin-treated rats.
2.3. Conventional light and electron microscopy study
Fourteen days after the last injection of doxorubicin or physiolog-
ical saline, the animals were weighed, killed, and the hearts rapidly
excised, rinsed in ice-cold 0.9% saline solution, blotted and weighed.
After ﬁxation by immersion in phosphate-buffered 10% formalin
for 24 h, the hearts were cut into anterior and posterior halves
and embedded in parafﬁn (n=6 hearts/group). Five micrometer-
thick serial sections were obtained and stained with hematoxylin
and eosin and picrosirius red. The sections stained with picrosirius
red were used to quantify the interstitial collagen volume fraction
using a Leica Qwin Software V 3.2.0 (Leica Imaging Systems Ltd.,
Cambridge, UK) in conjuction with a Leica DMR microscope (Leica
Microsystems Wetzlar GmbH, Wetzlar, Switzerland), videocamera
(Leica DC300F, Leica Microsystems AG, Heerbrugg, Switzerland) and
a computer online. Twenty high magniﬁcation ﬁelds (×400) of the
left ventricle free wall in each animal were randomly selected andthe values of the interstitial collagen volume fraction expressed in
percentage of the total area of the left ventricle.
Samples of myocardial tissue (1 mm3) from the left ventricular free
wall of rats treated with 15 mg/kg of doxorubicin and controls were
processed for transmission electron microscopy (n=4 hearts/group).
After ﬁxation by immersion in 2.5% glutaraldehyde in cacodylate
buffer and post-ﬁxation in 1% osmium tetroxide, ultrathin sections
were double-contrasted with uranyl acetate and lead citrate and exam-
ined in a Zeiss EM109/900 electronmicroscope (Carl Zeiss, Oberköchen,
Germany) at 80 kV. Considering that a common feature of congestive
heart failure is pulmonary congestion and consequent increased lung
weight, both lungs were rapidly excised together, rinsed in cold saline,
blotted, and weighed.
2.4. Immunoﬂuorescence
For immunoﬂuorescence study, sections (5 μm)were transversally
cut from frozen hearts (n=5 hearts/group) obtained 14 days after
the last injection of doxorubicin or saline. Immunolabeling
was done using antibodies anti-dystrophin (internal domains, rabbit
polyclonal, 1:200, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), anti-albumin (mouse monoclonal-FITC conjugated, 1:600,
Bethyl Laboratories Inc., Montgomery, TX, USA), and anti-calpain
(rabbit polyclonal, 1:100, Santa Cruz Biotechnology Inc.). Secondary
antibodies ﬂuorescein-conjugated anti-rabbit IgG and anti-mouse IgG,
diluted 1:400 (Vector Laboratories Inc., Burlingame, CA, USA) were
used. Immuﬂuorescence staining for albumin was used to evaluate
the sarcolemmal permeability of cardiomyocytes. These sections were
also stained with wheat germ agglutinin (WGA) conjugated with
Texas red (Vector Laboratories) to evaluate the structural integrity of
the plasma membranes. WGA is a carbohydrate-binding protein
that selectively recognizes sialic acid and N-acetylglucosaminyl sugar
residues basically found in the plasma membranes. All sections were
analyzed with Leica DM 6000M microscope equipped with Leica
AF6000 Deconvolution System (Leica Microsystems). For analysis of
the integrity of myoﬁlaments, double imunolabeling was done using
primary antibody anti-cardiacmyosin heavy chain (mousemonoclonal,
1:200, Abcam, Cambridge, MA, USA) followed by phalloidin complexed
to Alexa Fluor 594 (1:1000, Molecular Probes, OR, USA) in 0.1% BSA
at 37 °C for actin staining. Deconvolution analysis of the images was
analyzed with a Leica DM 6000M microscope using the Leica LAS-AF
software (version 1.8.0 build 1346).
2.5. Western blot analysis
To determine the amount of dystrophin in doxorubicin-treated
and control hearts, western blot was performed 14 days after the
last injection. Freshly isolated hearts (n=3 to 5 animals/group)
were washed in cold saline and the left ventricles were separated
and homogenized in extraction buffer with protease inhibitors
(Sigma-Aldrich, Inc., Saint Louis, MO, USA). Protein extract (50 μg
protein/well) was separated on a 5% and 10% polyacrylamide gel,
and transferred to nitrocellulose membrane (Hybond-ECL, Amersham
Pharmacia Biotech, Amersham, UK). After blocking with 5% skimmed
milk/TBS-T for 24 h, the blots were incubated overnight at 4 °C with
the antibodies anti-dystrophin (internal domains, rabbit polyclonal,
1:500, Santa Cruz Biotechnology Inc.) and anti-calpain-1 (goat poly-
clonal, 1:250, Santa Cruz Biotechnology Inc.). The blots were then
washed and incubated with secondary antibodies HRP-conjugated
goat anti-rabbit IgG, goat anti-mouse IgG and donkey anti-goat
IgG, diluted 1:20,000 (Santa Cruz Biotechnology Inc.) for 40 min.
The membranes were washed, developed with the ECL (Amersham
Pharmacia Biotech) and gel documentation was made by Molecular
Imager ChemiDoc XRS System (Bio-Rad, Richmond, CA, USA). Images
were analyzed using the Image J program (National Institutes of Health,
available at http://rbs.info.nih.gov/nih-image/), using the “gel analysis”
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the integrated density value (IDV) of the band, corresponds to arbitrary
units (AU). α-Tubulin mouse monoclonal, diluted 1:1000 (Santa Cruz
Biotechnology Inc.) was used as a protein loading control.
2.6. Echocardiography
Echocardiographic study was performed as described previously
(Campos et al., 2008) in doxorubicin-treated animals and controls,
7 and 14 days after the last injection of doxorubicin or saline
(n=5–8 animals/group). Brieﬂy, the internal diameters of left and
right ventricles at systole and diastole were obtained from left ven-
tricular M-mode measurements at the level of papillary muscles.
These parameters were used to calculate ejection fraction (EF) by
Teichholz method (Teichholz et al., 1976) and fractional shortening
(FS), both used as left ventricle systolic function parameters. Heart
rate was measured with pulsed Doppler and all measurements are
expressed as the mean of three consecutive cardiac cycles.
2.7. Statistical analysis
Multiple comparisons were done using one-way ANOVA followed
by Tukey or Dunnet post-tests. Comparisons of two groups were
made using Student's t-test. The survival rates were constructed
using the Kaplan–Meier curve, and differences in mortality were
compared using the log-rank (Mantel Cox) test. All data are expressedFig. 1. Mortality rate and body, heart and lung weights. (A) Curves of actuarial mortality o
end of experiment (n=10 animals per group; the results are representative of 2 differen
The mean ﬁnal body weight of rats given 7.5 and 15 mg/kg was signiﬁcantly reduced as com
and controls. (D) Mean lung weight/body weight ratios of rats given doxorubicin and contras mean±standard error and Pb0.05 was considered statistically
signiﬁcant.
3. Results
3.1. General observations and survival rate
Animals treated with doxorubicin were hypoactive presenting
piloerection and periocular and nasal exudation after the three ﬁrst
injections, alterations more pronounced in animals treated with
7.5 and 15 mg/kg of drug. Doxorubicin treatment had an impact on
survival rate. Doxorubicin-treated rats at doses of 7.5 and 15 mg/kg
showed survival rates of 71.4% and 28.6%, respectively, observed
during the experimental period of 28 days. Control and 3.75 mg/kg
of doxorubicin treated rats presented a 100% survival rate (Fig. 1A).
3.2. Body, heart and lung weights
Doxorubicin treatment had a dramatic impact on body, heart and
lung weights. The mean ﬁnal body weights (BW) of rats given 3.75,
7.5 and 15 mg/kg of doxorubicin were 360.0±40.72, 323.0+56.47
and 285.8±82.59 g, respectively, representing a reduction in BW
gain of 11.76%, 20.83% and 30.14%, respectively, compared with that
of controls, 408±32.70 g (Fig. 1B).
At autopsy, the hearts of rats given doxorubicin were dilated,
soft and ﬂabby associated with ascites. The mean heart weightsf rats given doxorubicin and controls. The survival rate was determined daily until the
t experiments). (B) Mean ﬁnal body weights of rats given doxorubicin and controls.
pared to controls. (C) Mean heart weight/body weight ratios of rats given doxorubicin
ols. Data are expressed as mean±S.D.
Fig. 2. Western blot analysis of dystrophin. The amount of dystrophin in the
doxorubicin-treated animals and control groupwasmeasured 14 days after the last injec-
tion of doxorubicin or saline and expressed in arbitrary units (AU). The amounts of dystro-
phin in all treated groups were signiﬁcantly reduced as compared with non-treated
controls and not statistically different among themselves.α-Tubulinwas used as a protein
loading control. (A, B). When all samples, including controls and treated animals,
were considered, a negative linear correlation (n=33, r2=0.6386, Pb0.0001) was
found between the relative amount of the dystrophin and the dose of doxorubicin
administered (C). Data are expressed as mean±S.D.
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1.022±0.20 and 0.727±0.17 g, respectively) were 1.69%, 21.4% and
44.1% lower, respectively, as compared to that of controls (1.301±
0.09 g). The values observed in rats given a total dosage of 7.5 and
15 mg/kg were different from the mean HW values in controls, as
revealed by a Pb0.05 and Pb0.01, respectively. However, the
mean HW/BW (×103) ratios of rats given 3.75, 7.5 and 15 mg/kg of
doxorubicin were 3.220±0.36, 3.226±0.14 and 3.086±0.78, respec-
tively, as compared to that of controls, 3.148±0.16. These HW/BW
ratios observed in rats given doxorubicin were not different from
the mean HW/BW ratio in controls (Fig. 1C).
The mean lung weights (LW) of rats given 3.75, 7.5 and 15 mg/kg
of doxorubicin (2.159±0.30, 2.541±0.83 and 2.802±0.55 g, respec-
tively) were 3.05%, 21.2% and 33.7%, respectively, higher in compari-
son with that of control rats (2.095±0.14 g). There was a tendency
toward an increased LW in animals treated with doxorubicin as com-
paredwith that of controls. Themean LW/BW ratios of rats given 3.75,
7.5 and 15 mg/kg of doxorubicin were 5.941±1.45, 6.792±2.81
and 9.963±4.37, respectively, representing an augmentation of
12.45%, 28.56% and 88.58%, respectively, compared with that control
rats, 5.283±0.29. The mean LW/BW ratios of rats given 3.75 and
7.5 mg/kg of doxorubicin were not signiﬁcantly different from that
of controls. The LW/BW ratio in rats given a total dosage of 15 mg/kg
was signiﬁcantly different from that of controls (Fig. 1D).
3.3. Histopathology
The control hearts did not present any histopathological change.
Microscopic changes were observed in the hearts of all doxorubicin-
treated groups, more pronounced in that treated with the higher
dose, and characterized by swollen and vacuolated myocytes, loss or
disorganization of myoﬁbrils, interstitial edema, and interstitial inﬁltra-
tion by lymphomononuclear cells and ﬁbroblasts. Interstitial ﬁbrosis
was evaluated by picrosirius red staining in control and doxorubicin-
treated hearts. The interstitial collagen volume fractions in animals
treated with 3.75, 7.5 and 15 mg/kg of doxorubicin were 1.718±
0.42%, 1.799±0.38% and 2.489±0.53%, respectively, representing
86.5%, 95.3% and 170%, respectively, markedly increased (Pb0.001) as
compared to the volume fraction of the control group, 0.921±0.41%.
The interstitial collagen volume fractions were not statistically different
in groups treated with 3.75 and 7.5 mg/kg of doxorubicin.
3.4. Dystrophin analysis
The amounts of dystrophin in tissue samples were analyzed by
western blot and then quantiﬁed. The relative optical densities were
evaluated and expressed as arbitrary units (AU). The amounts of dys-
trophin in ventricles of doxorubicin-treated animals given 3.75, 7.5
and 15 mg/kg were markedly reduced, 2500±170, 2156±926 and
1882±1020 AU, respectively, representing 63.1%, 68.2% and 72.2%
lower, respectively, in comparison with the amount of dystrophin of
control animals, 6780±764 AU. The relative amounts of dystrophin
in animals treated with 3.75, 7.5 and 15 mg/kg of doxorubicin were
not different among themselves (Fig. 2A–B).
When all samples, including controls and treated animals, were con-
sidered, a negative linear correlation (n=33, r2=0.6386, Pb0.0001)
existed between the relative amount of the dystrophin and the dose
of doxorubicin administered (Fig. 2C).
Concerning the immunoﬂuorescent detection of dystrophin, foci
of myocardial lesion with reduced or loss of sarcolemmal dystro-
phin, which demarcates the cellular perimeter, were observed in
doxorubicin-treated rats, more pronounced in hearts of animals
given 7.5 and 15 mg/kg, as compared with control hearts showing
abundant signal for this protein. Besides, dystrophin is also situated
at the T-tubules system in a network pattern extending at the ven-
tricular myocytes cytoplasm, corresponding to an intermyoﬁbrillarnetwork; this intermyoﬁbrillar network was more strikingly demar-
cated in the cytoplasm of myocytes from doxorubicin-treated hearts.
Plasma membrane integrity could be clearly and similarly identiﬁed
by WGA staining in all groups. That is, the merge of dystrophin and
WGA ﬂuorescence images clearly delineated the cardiomyocytes in
all groups, with blocks of cardiomyocytes exhibiting the reduction or
loss of dystrophin signal in three different dosages of doxorubicin-
treated hearts, more prominent in hearts of animals treated with
7.5 and 15 mg/kg (Fig. 3).
3.5. Sarcolemmal integrity and permeability analysis
The assessment of sarcolemmal permeability with albumin
staining showed that doxorubicin treatment rendered the sarcolemma
Fig. 3. Immunoﬂuorescence analysis of dystrophin and structural integrity analysis of the sarcolemma (cross sections of the myocardium). The immunoﬂuorescent signal for dys-
trophin (green ﬂuorescence) clearly showed foci of myocardial lesion with reduced or loss of dystrophin signal in DOX-treated hearts (arrows), more pronounced in hearts treated
with 7.5 and 15 mg/kg. Control hearts showed abundant signal for this protein. Sarcolemmal structure could be clearly and similarly identiﬁed by WGA staining (red ﬂuorescence)
in all groups in which the sarcolemmal integrity was preserved. Scale bars indicate 50 μm.
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wasmainly localized in vascular lumina and in the interstitium forming
a delicate network. In doxorubicin-treated hearts with 7.5 and 15 mg/
kg, albumin labelingwasmore intense in the interstitium and,most im-
portantly, in the cytoplasm of spread large blocks of myocytes. In hearts
treated with 3.75 mg/kg of doxorubicin, albumin was mainly localized
in the interstitium, although the cytoplasm of a few spread blocks of
myocytes showed faint albumin ﬂuorescence. Sarcolemmal structure
could be clearly and similarly identiﬁed by WGA staining in all groups,
which is consistent with increased sarcolemmal permeability instead
of cell rupture. Fig. 4 illustrates the ﬁndings in the myocardium of
rats treated with 3.75 and 15mg/kg of doxorubicin as compared
with control saline.
3.6. Calpain analysis
Doxorubicin is known to cause intracellular calcium overload
(Emanuelov et al., 2010; Szenczi et al., 2005). This could lead to acti-
vation of calcium-dependent proteases, mainly calpains, inducing
proteolysis of cellular constituents. The expression of calpain exam-
ined by immunoﬂuorescence was strikingly increased in the cyto-
plasm of cardiomyocytes from doxorubicin-treated rats as compared
to control myoﬁbers. Besides, sarcolemmal structures could be clearly
delineated by WGA staining in all groups thus reﬂecting the integrity
and preservation of the plasma membranes (Fig. 5, left panels).
The amounts of calpain in tissue samples were analyzed and quan-
tiﬁed by western blot. The amounts of calpain, expressed in arbitrary
units (AU), in animals given doxorubicin were markedly increased,
5881±44, 5489±105 and 6121±483 AU, for animals given 3.75,7.5 and 15 mg/kg, respectively, representing values 96.9%, 83.8% and
104.9% higher, respectively, in comparison with the amount of calpain
determined in control animals, 2986±384 AU (Fig. 5, right panels).
3.7. Dantrolene attenuates doxorubicin-induced survival rate and
dystrophin disruption and normalizes calpain levels
In order to determine if administration of dantrolene, a calcium
blocker agent that acts by binding to the ryanodine receptors directly
decreasing the release of calcium from the sarcoplasmic reticulum in
striated muscles (Kobayashi et al., 2009; Santonastasi and Wehrens,
2007), could reduce mortality and prevent dystrophin expression re-
duction in the myocardium, an additional experiment was done
(n=14 rats/group): control and doxorubicin-treated hearts (15 mg/kg
of body weight in the same schedule described above) were treated
with dantrolene (5 mg/kg of body weight via i.p. immediately after
each dose of doxorubicin administered).
Rats treated with doxorubicin plus dantrolene presented signiﬁ-
cantly decreased mortality rate, 28.5%, in comparison to the mortality
rate of rats treated with doxorubicin only, 64.2%, alongside myocar-
dial dystrophin reduction, in comparison with rats treated with
doxorubicin only, which represents a strikingly signiﬁcant reduction
of 2.25 times. Controls (with or without dantrolene) presented a
100% survival rate (Fig. 6).
The mean amount of dystrophin in left ventricles of rats given
doxorubicin was strikingly reduced, 1882±1020 AU, in compari-
son with the mean dystrophin amounts in controls given saline,
6780±764 AU (3.6 times less), and controls given saline plus
dantrolene, 7019±1651 AU (3.7 times less). The mean dystrophin
Fig. 4. Structural integrity analysis of the sarcolemma. Immunolabeling for albumin (green ﬂuorescence) and plasma membranes (WGA, red ﬂuorescence) (cross sections of the
myocardium). In control rats we observed that albumin was mainly localized in the interstitial space as a delicate network and in the vascular lumina. In doxorubicin-treated hearts
(the ﬁndings with the doses of 3.75 and 15 mg/kg are illustrated), albumin immunolabeling was more intense in the interstitial space compared with controls. Spread large blocks
of myocytes became positive showing intracytoplasmatic albumin labeling. Sarcolemmal structure could be clearly and similarly identiﬁed by WGA staining in all groups in which
the plasma membrane integrity was preserved. The merge of albumin andWGA ﬂuorescent images clearly delineates the cardiomyocytes, with blocks of cardiomyocytes exhibiting
a uniformly diffuse pattern of cytoplasmic albumin staining in doxorubicin-treated hearts. Scale bars indicate 50 μm.
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was 5246±1255 AU, statistically not different from controls, a
value 2.8 times higher in comparison with the amount of dystrophin
in ventricles of rats given doxorubicin only (Fig. 6).
At 14 days after the last injection of doxorubicin, the controls (with
or without dantrolene) displayed normal dystrophin distribution at
the cellular perimeter in all cardiomyocytes with clear delineation of
the cells; the intermyoﬁbrillar dystrophin was lightly marked (n=5
rats/group). In contrast, as demonstrated above, the dystrophin
immunolabeling was focally reduced or completely lost in groups of
cardiac myocytes of doxorubicin-treated rats (n=6 animals/group).
The myocardium of rats given doxorubicin plus dantrolene clearly
exhibited preserved sarcolemmal dystrophin expression except for
a few spread foci of dystrophin expression reduction/loss (n=5
rats/group). The intermyoﬁbrillar dystrophin was more evidently
demarcated in doxorubicin-treated hearts as compared with the
intermyoﬁbrillar dystrophin of doxorubicin plus dantrolene-treated
hearts (Fig. 6).
The mean amount of calpain in left ventricles of rats given doxoru-
bicin was strikingly increased, 6121±483 AU, in comparison with the
mean calpain amounts in controls given saline, 2986±384 AU, and
controls given saline plus dantrolene, 2311±182, an increase of 2.1
times and 2.6 times, respectively. The mean calpain amount in ventri-
cles of animals given doxorubicin plus dantrolenewas 2480±694 AU,
a value 2.6 times lower in comparison with that in ventricles of ratsgiven doxorubicin only, not statistically different from controls (with
or without dantrolene) (Fig. 6).
3.8. Immunoﬂuorescence of actin and myosin
Deconvolution analysis of double immunolabeling for myosin and
actin in control cardiomyocytes showed that both actin and myosin
were regularly stained, actin appearing as red ﬂuorescent I bands
(similar to ladder rungs) and myosin appearing as green ﬂuorescent
A bands (similar to brick piles) within the sarcomeric structures. In
contrast, the doxorubicin-treated myocardium, more pronounced
with the dose of 15 mg/kg of the drug, showed diffuse foci of dis-
rupted actin and myosin, reﬂecting disarrangement of the sarcomeric
structure (Fig. 7A–B).
3.9. Ultrastructure
The ultrastructural examination of the control myocardium
was similar to that reported in the literature (Rossi and Carillo,
1983). The ultrastructure of the myocardium from rats treated
with 15 mg/kg of doxorubicin presented changes characterized
by myoﬁbrillar derangement and fragmentation or dissolution of
myoﬁbrils, intracellular edema, marked mitochondrial swelling with
rupture of cristae and great number residual bodies (Fig. 7C–F).
Fig. 5. Immunoﬂuorescence analysis of calpain and sarcolemmal integrity (cross sections of the myocardium). The expression of calpain examined by immunoﬂuorescence
was strikingly increased in the cytoplasm of cardiomyocytes from doxorubicin-treated rats as compared to control myoﬁbers. Besides, sarcolemmal structures could be clearly
delineated by WGA staining in all groups thus reﬂecting the integrity and preservation of the plasma membranes. Sarcolemmal structure could be clearly and similarly identiﬁed
by WGA (red ﬂuorescence) staining in all groups in all groups in which the plasma membrane integrity was preserved. The merge of calpain and WGA clearly showed the calpain
expression in the intracellular space of cardiomyocytes. Scale bars indicate 50 μm. The amounts of calpain in tissue samples were analyzed by western blot and then quantiﬁed.
The amounts of calpain, expressed in arbitrary units (AU), in animals given doxorubicin were markedly increased, in comparison with the amount of calpain determined in
control animals. α-Tubulin was used as a protein loading control. Data are expressed as mean±S.D.
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study for actin and myosin by using deconvolution microscopy.
3.10. Echocardiography
The mean heart rate was not signiﬁcantly different in controls
(320.3±15.5 bpm and 275.6±17.6 bpm) 7 and 14 days, respectively,
after the last injection of saline and treated rats given a total dosage
of 3.75 mg/kg (322.5±32.1 bpm and 301.4±32.3 bpm), 7.5 mg/kg
(289.0±19.0 bpm and 291.5±6.0 bpm), and 15 mg/kg (302.0±15.4
and 280.0±27.6 bpm) 7 and 14 days, respectively, after the last injec-
tion of doxorubicin.
The mean ejection fraction-Teichholz (EF) was signiﬁcantly de-
creased, less 9.52%, 7 days after the last injection of 15 mg/kg of doxo-
rubicin (72.2±2.2%) compared to that of controls (79.8±2.2%). The
values observed in doxorubicin-treated rats given cumulative doses
of 3.75 mg/kg (75.9±2.5%) and 7.5 mg/kg (75.5±4.8%) were not dif-
ferent from the mean EF in controls. In contrast, the mean EF values
were signiﬁcantly decreased, 8.1%, 9.7% and 12.6% less, 14 days afterthe last injection of 3.75 mg/kg (74.3±1.9%), 7.5 mg/kg (73.0±3.1%)
and 15 mg/kg (70.7±2.3%) of doxorubicin, respectively, in comparison
with the EF value in control rats (80.9±2.3%) (Fig. 8, left and middle
upper graphs).
The mean fractional shortening (FS) was decreased 10.4% 7 days
after the last injection in animals given a total dosage of 15 mg/kg of
doxorubicin (38.5±1.7%) compared to that of controls (43.0±2.7%).
The values observed in rats given a total dosage of 3.75 mg/kg
(40.5±2.2%) and 7.5 mg/kg (41.0±2.4%) were not different from
the mean FS value in controls. In contrast, the mean FS values were
signiﬁcantly decreased, 11%, 12.8% and 20.5% less, 14 days after the
last injection of doxorubicin in rats given cumulative doses of
3.75 mg/kg (39.5±2.4%), 7.5 mg/kg (38.7±1.7%) and 15 mg/kg
(35.3±2.8%), respectively, in comparison with the FS values in con-
trols (44.4±3.0%) (Fig. 8, left and middle lower graphs).
These ﬁndings clearly indicate that contractile impairment oc-
curred in an early stage in the doxorubicin group. Moreover, when
all samples, including controls and treated rats, were considered,
a negative linear correlation (n=17, Pb0.001) was found between
Fig. 6. (Left upper panel). Western blot analysis of myocardial dystrophin in rats given saline (Control), saline plus dantrolene (Control+DT), doxorubicin (DOX) and doxorubicin
plus dantrolene (DOX+DT). The mean amount of dystrophin in DOX hearts was signiﬁcantly reduced in comparison with controls (with or without dantrolene; *, Pb0.001) and
DOX+DT (#, Pb0.001). The mean amount of dystrophin in the DOX+DT hearts was slightly decreased as compared to controls, but not statistically different. (Right upper
panel) Representative images of immunoﬂuorescent dystrophin signals (green ﬂuorescence) in the myocardium of the four experimental groups. The controls (with or without
dantrolene) show normal distribution at the cellular perimeter and lightly marked at the intermyoﬁbrillar location in all cardiomyocytes. DOX rats show diffuse foci of complete
loss or reduction (arrows) of sarcolemmal dystrophin and more demarcated intermyoﬁbrillar dystrophin. DOX+DT rats show almost normal distribution of dystrophin at
the cellular perimeter and at the intermyoﬁbrillar location, except for a few cells showing reduced expression of this protein (arrows). α-Tubulin was used as a protein loading
control. Scale bars indicate 50 μm. (Left lower panel) Western blot analysis of myocardial calpain in controls (with or without dantrolene; *, Pb0.001) and DOX+DT
(#, Pb0.001). The mean amount of calpain in DOX+DT rat hearts was similar to those of controls. (Right lower panel) Curves of actuarial mortality of rats given saline (Control),
saline plus dantrolene (Control+DT), doxorubicin (DOX) and doxorubicin plus dantrolene (DOX+DT). The survival rate was determined daily until the end of the experiment
(n=10–12 animals per group).
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EF and FS, 14 days after the last doses of saline or drug (Fig. 8, upper
and lower right graphs).
Themean EF 7 days and 14 days after the last injection of 15 mg/kg
of doxorubicin plus dantrolene was 80.7±0.8% and 79.1±3.8%, re-
spectively, not statistically different from controls given dantrolene
(80.3±1.4% and 80.8±1.1%, respectively) or saline (79.8±2.2%
and 80.9±2.3%, respectively). In addition, the mean FS in rats 7 days
and 14 days after the last injection of 15 mg/kg of doxorubicinplus dantrolene was 44.2±0.7% and 42.6±3.4%, respectively, not sta-
tistically different from controls given dantrolene (43.3±1.9% and
45.5±0.8%, respectively) or saline (43.0±2.7% and 44.4±3.0%, re-
spectively). In contrast, the mean EF 7 days and 14 days after the last
injection were signiﬁcantly decreased in rats given doxorubicin only
(72.2±2.2% and 70.7±2.3%, respectively) in comparison with rats
given doxorubicin plus dantrolene (80.3±1.4% and 80.8±1.1%, re-
spectively). The mean FS 7 days and 14 days after the last injection
were signiﬁcantly decreased in rats given doxorubicin only (38.5±
Fig. 7. Immunoﬂuorescent analysis of actin and myosin and myocardium ultrastructure. (A) Representative deconvolution image of double immunolabeling for myosin (green
ﬂuorescence) and actin (red ﬂuorescence) of control myocardium. Both sarcomeric proteins are regularly labeled, showing distinctly the presence of clearly red ﬂuorescent I
bands corresponding to actin (appearing as ladder rungs) and green ﬂuorescence A bands corresponding to myosin (appearing as brick piles) within the sarcomeric structures
throughout the cardiac muscle cells (arrows) Scale bar indicate 50 μm. (B) Representative deconvolution image of doxorubicin-treated myocardium. Diffuse disruption of both
actin and myosin can be clearly seen, reﬂecting disarrangement of the sarcomeric structure (arrows). This appearance is in accordance with the ultrastructural ﬁndings, reﬂecting
disarrangement of the sarcomeric structure. Scale bars indicate 50 μm. (C, E) Representative images of control myocardium. Ultrastructural analysis showed the actin and myosin
ﬁlaments arranged lengthwise in myoﬁbrils, showing a symmetrical and parallel organization, presenting as arrays of myoﬁbrils separated by rows of mitochondria. Scale bars
indicate 2 μm in A and 1 μm in C. (D, F) Representative images of the doxorubicin-treatedmyocardium. Themyocardium of doxorubicin-treated rats presented changes characterized
by fragmentation and dissolution of myoﬁbrils with derangement of sarcomeric structures implicating the most abundant proteins actin and myosin (arrows), intracellular
edema (*), marked mitochondrial swelling with disruption of cristae (arrow heads) and lipofuscin bodies (thin arrows). (Inset) Typical residual body showing granular material
(RB) appearing in the company of a lipid droplet (L). Scale bars indicate 2 μm in C and D, 0.5 μm in the inset of D and 1 μm in E and F.
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doxorubicin plus dantrolene (44.2±0.7% and 42.6±3.4%, respectively)
(Fig. 9). These ﬁndings indicate the preservation of cardiac function in
animals that received dantrolene.
4. Discussion
The mortality rates and cardiac morphological changes in the pre-
sent study have been extensively described in humans (Steinhertz
et al., 1991) and experimental animals (Arola et al., 2000; Takemura
and Fujiwara, 2007). In addition, the mean absolute HW of rats
given 7.5 and 15 mg/kg of doxorubicin was lower as compared to
controls, and the mean HW/BW ratios of rats given doxorubicinwere similar to that of controls. The deconvolution analysis and
the ultrastructural study could demonstrate myoﬁbrillar dissolution
and disruption with formation of residual bodies in the hearts of
doxorubicin-treated rats. Residual bodies, as seen by electron micros-
copy, correspond to brown granules of lipofuscin by light microscopy,
usually appearing in the company of lipids. Lipofuscin, often called
age or senescence pigment is considered a hallmark of aging process,
although does not cause aging. The pigment results from oxidative
stress of membrane phospholipids and neutral fats (Brunk et al.,
1992), reﬂecting organs atrophy, especially heart and liver. Our ﬁndings
support recent studies showing that cultured neonatal cardiomyocytes
(Maejima et al., 2008) and endothelial progenitor cells (Spallarossa
et al., 2010) treated with low subapoptotic doses of doxorubicin
Fig. 8. The mean ejection fraction-Teichholz (EF) was signiﬁcantly decreased 7 days after the last injection of 15 mg/kg of doxorubicin compared to that of controls. The values ob-
served in doxorubicin-treated rats given cumulative doses of 3.75 mg/kgwere not different from themean EF in controls. In contrast, themean EF values were signiﬁcantly decreased
14 days after the last injection of 3.75, 7.5 and 15 mg/kg of doxorubicin in comparisonwith the EF value in control rats (left andmiddle upper graphs). Themean fractional shortening
(FS) was decreased 7 days after the last injection in animals given a total dosage of 15 mg/kg of doxorubicin compared to that of controls. The values observed in rats given a total
dosage of 3.75 and 7.5 mg/kg were not different from the mean FS value in controls. In contrast, the mean FS values were signiﬁcantly decreased 14 days after the last injection
of doxorubicin in rats given cumulative doses of 3.75, 7.5 and 15 mg/kg in comparison with the FS values in controls (left and middle lower graphs). When all samples, including
controls and treated rats, were considered, a negative linear correlation (n=16, Pb0.0001) was found between the total dosage of doxorubicin and both systolic function indices,
EF and FS, 14 days after the last doses of saline or drug (right upper and lower graphs).
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to these authors, the senescent-like alterations would indicate a novel
mechanism of doxorubicin induced myocardial dysfunction.
The immunoﬂuorescence study allowed us to characterize mor-
phologically the loss of sarcolemmal dystrophin, more prominent
in the hearts of rats given cumulative doses of 7.5 or 15 mg/kg.
The intermyoﬁbrillar pattern of dystrophin labeling was more pro-
nounced in the ventricular cardiomyocytes of doxorubicin-treated
hearts. This agrees with previous observations showing that in the di-
lated, failing human hearts the intermyoﬁbrillar pattern of dystrophin
appeared increased in comparison with normal human or rat myocar-
dium in parallel with the dilatation of T-tubules (Kostin et al., 1998,
2000; Schaper et al., 1991). It can be speculated that the increase in
intermyoﬁbrillar expression might be seen as a recovery strategy of
cardiomyocytes to improvemyoﬁbrillar stability and lateral force trans-
mission. The western blot analysis disclosed a marked signiﬁcantly
decreased amount of dystrophin in the hearts of rats given cumula-
tive doses of 3.75, 7.5 and 15 mg/kg of drug, less 63%, 68% and 72%,
respectively, as compared to controls.
The functional consequences of theseﬁndings as evaluated by trans-
thoracic wall echocardiography disclosed early signiﬁcantly decreased
systolic function indices of left ventricle ejection fraction-Teichholz
or fractional shortening 7 days after the last injection of doxorubicin
in animals given a total cumulative dose of 15 mg/kg; both ejection
fraction and fractional shortening were signiﬁcantly decreased inall doxorubicin-treated groups 14 days after the last injection of doxo-
rubicin in comparison to control values 14 days after the last dose of
saline. As well, the linear regression analysis conﬁrmed that doxorubi-
cin induced a decrease in these contractile performance indices. These
cardiac functional ﬁndings are corroborated by morphological ﬁndings
regarding increased LW/BW ratios in doxorubicin-treated rats, consis-
tent with the transition or an established heart failure. In contrast,
dantrolene-treated animals preserved the cardiac function as compared
to animals given only doxorubicin.
Numerous studies have pointed out the physiopathologic role
of dystrophin with its associated glycoproteins on myocardial con-
tractile performance. Dystrophin, localized beneath the sarcolemma
linking actin to the extracellular matrix through the membrane
spanning glycoproteins through the n-, c- and internal domains, is
the most important structure of the cytoskeleton proteins. The lack
of dystrophin in the hearts of patients with Duchenne muscular
dystrophy (DMD) as well as in mdx mice constitutes the structural
basis for the development of dilated cardiomyopathy (Danialou
et al., 2001; Lapidos et al., 2004; Tidball and Wehling-Henricks,
2007; Wallace and McNally, 2009). In addition, dystrophin loss has
been related to end-stage cardiomyopathies and proposed as a com-
mon route for myocardial dysfunction and progression to advanced
heart failure (Kawada et al., 2005; Toyo-Oka et al., 2004). More re-
cently, therapeutic dystrophin restoration to almost normal levels in
cardiac and skeletal muscle in mdx mice has been demonstrated to
Fig. 9. The mean ejection fraction-Teichholz (EF) and fractional shortening (FS) of rats given saline (Control), saline plus dantrolene (Control+DT), doxorubicin (DOX) and
doxorubicin plus dantrolene (DOX+DT). The mean EF and FS was signiﬁcantly different of rats given DOX only as compared to rats given DOX+DT 7 days and 14 days after
the last injection of drug or saline. No differences were observed in FS and EF of rats given DOX+DT as compared to Control and Control+DT rats, 7 days and 14 days after the
last injection of drug or saline. Data are expressed as mean±S.D.
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muscle strength (Wu et al., 2008).
Taking into account that doxorubicin is known to induce early
oxidative stress, lipid peroxidation and production of toxic lipid alde-
hydes, including 4-hydroxy-2-nonenal (HNE) (Jungsuwadee et al.,
2006; Liu et al., 2006; Luo et al., 1997), and dystrophin-deﬁcientmuscle
ﬁbers are abnormally susceptible to mechanical and oxidative stresses
with consequent sarcolemmal damage (Danialou et al., 2001; Dudley
et al., 2006; Lapidos et al., 2004; Tidball and Wehling-Henricks, 2007;
Wallace and McNally, 2009), the immunoﬂuorescence double staining
for albumin and sarcolemmal delineationwithWGAwas done to exam-
ine the integrity of the sarcolemma in control and doxorubicin-treated
rats. For the ﬁrst time, the identiﬁcation of cytoplasmic albumin to
evaluate sarcolemmal permeability gave evidence of sarcolemmal
damage in rats treated with doxorubicin, more pronounced in rats
given 7.5 and 15 mg/kg. The plasma membranes of cardiomyocytes
were clearly delineated in all groups with WGA, which is consistent
with increased sarcolemmal membrane permeability instead of
cell rupture, which may reﬂect a reversible damage. The increased
sarcolemmal permeability in doxorubicin-treated rats may be a
consequence of either oxidative damage to the plasma membrane
of cardiomyocytes or impairment of the dystrophin-glycoprotein
complex. In this respect, it is important to emphasize that animals
given doxorubicin plus dantrolene presented no alteration in
the sarcolemmal permeability, similarly to control rats (data
not shown). Taken together, these ﬁndings provide evidence that
several common hypotheses regarding the cause of cardiac muscle
damage induced by doxorubicin treatment can be integrated intoa common pathophysiological pattern involving interactions be-
tween oxidative stress and hyperfragility of the sarcolemma.
The detection of signiﬁcantly increased expression of intracellular
calpain points to the implication of this protease activated by increased
intracellular calcium concentration in the mechanism of dystrophin
loss and proteolysis. Previous study demonstrated that calpains digest
dystrophin very rapidly when the calcium concentration is compatible
with their activation and it was clear that calpains ﬁrst give rise
to large dystrophin products and suggest that dystrophin antibodies
speciﬁc to the central domain of the molecule should be used to detect
dystrophin for diagnostic purposes (Cottin et al., 1992). This opinion is
strongly supported by the demonstration that rats treated with
15 mg/kg of doxorubicin plus 5 mg/kg of dantrolene presented levels
of myocardial dystrophin and calpain similar to those of control rats
treated with saline or saline plus dantrolene. The levels of myocardial
dystrophin and calpain in animals treated with doxorubicin plus
dantrolene were 2.8 times higher and 2.6 times lower, respectively,
in comparison with the levels of heart dystrophin and calpain in
rats treated with doxorubicin only. Moreover, the survival rate of
doxorubicin plus dantrolene rats was 2.25 times higher as compared
with that rats treated with doxorubicin only. Calcium release from
the sarcoplasmic reticulum (SR) stores, mediated by cardiac type-2
ryanodine receptors (RyR2), is required for muscle contraction and
electrical signals that determine the heart rhythm (Wehrens et al.,
2005). The cytosolic calcium levels are very low (~100 nM) during dias-
tole increasing tenfold during systole (1 μM). However, intracellular
calcium overload from SR leak activates proteases, such as calpain,
which can degrade cytoskeletal and membrane proteins, including
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2004;Whitehead et al., 2006;Willis et al., 2009). In addition, dantrolene
is known to bind to both ryanodine receptors (skeletal muscle: RyR1
and cardiac: RyR2) of the SR inhibiting calcium leak by correcting
inter-domain interactions within RyR2 in cardiomyocytes isolated
from failing dog hearts thus inhibiting calcium leak through RyR2
(Kobayashi et al., 2009). On the other hand, studies on isolated rat car-
diac SR have shown that doxorubicin and its metabolite doxorubicinol
induce an increased calcium release from SR (Pessah et al., 1990).
Recently investigation demonstrated that cultured cardiomyocytes
treated with doxorubicin present increased intracellular calcium
concentration release from the SR via RyR2 (Emanuelov et al., 2010).
5. Conclusions
This study offers novel and mechanistic data to clarify molecular
events that occur in the myocardium in doxorubicin-induced chronic
cardiomyopathy. Doxorubicin led to a marked reduction/loss in dys-
trophin membrane localization in cardiomyocytes and left ventricular
dysfunction, which might constitute, in association with sarcomeric
actin/myosin proteins disruption, the structural basis of doxorubicin-
induced cardiac depression. Moreover, increased sarcolemmal perme-
ability suggests functional impairment of the dystrophin-glycoprotein
complex in cardiac myoﬁbers and/or oxidative damage. Increased
expression of calpain, a calcium-dependent protease, was markedly
increased in cardiomyocytes of doxorubicin-treated rats. Dantrolene
strikingly improved survival rate and preservedmyocardial dystrophin,
calpain levels and left ventricular function, which supports the opinion
that calpain mediates dystrophin loss and myoﬁbrils degradation in
doxorubicin-treated rats. Studies are needed to further elucidate this
mechanism, mainly regarding speciﬁc calpain inhibitors, which may
provide new interventional pathways to prevent doxorubicin-induced
cardiomyopathy and heart failure.
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